ClinicalTrials.gg
RecruitingNCT07365527CEUSONUpdated Feb 27, 2026

Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases

An interventional study of Low-intensity contrast enhanced ultrasound and High-intensity contrast enhanced ultrasound in Liver Metastases From Colorectal Cancer, sponsored by Zealand University Hospital. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Zealand University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Colorectal Neoplasms by Zealand University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Colorectal Neoplasms · Zealand University Hospital.

Planned enrollment
5th of 11
48 · median 40
Started
2026
the only one that year
No phase
3 of 16
1 open now
Registered
16th of 16
by date

Among the 16 studies in Colorectal Neoplasms by Zealand University Hospital, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 16th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 16 studies in Colorectal Neoplasms by Zealand University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colorectal Neoplasms by Zealand University Hospital, or all of them as a file.
02

Study summary

This study is an investigator-initiated, randomized controlled trial enrolling patients with colorectal liver metastases. The objectives are to evaluate the safety and efficacy of contrast-enhanced ultrasound (CEUS)-mediated sonoporation as a potential therapeutic intervention and to investigate whether sonoporation can modulate the tumor microenvironment toward a more immune-active state

Read the detailed description

The trial is designed as an investigator-initiated, multicenter, prospective, randomized, controlled, two-arm, intervention trial with a matched historical control group aims to evaluate the therapeutic potential of contrast-enhanced ultrasound (CEUS) in patients with colorectal liver metastases (CLM). The primary objectives are to assess whether CEUS can modulate the tumor microenvironment and to determine the safety, tolerability, and feasibility of CEUS as a therapeutic modality. Eligible patients will be randomized to receive either low-intensity CEUS (LI-CEUS) or high-intensity CEUS (HI-CEUS) focused on a designated study metastasis. Safety, feasibility, and success-rate of the intervention will be registered. Minimum seven days post-intervention a biopsy of the study metastasis will be conducted. Subsequent analyses will compare immune cell infiltration, immune-related gene expression, and stromal and vascular remodeling in LI-CEUS- and HI-CEUS-exposed metastases versus historical controls.

03

Conditions studied

  • Liver Metastases From Colorectal Cancer

Keywords

  • liver metastasis
  • CEUS
  • Sonoporation
  • Contrast enhanced ultrasound
  • colorectal cancer
  • liver metastases
  • tumor microenvironment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years)
  • Ability to provide written
  • Histopathological confirmed colorectal adenocarcinoma
  • Scheduled for liver resection or ablation at the Rigshospital, or admitted to oncologic treatment due to colorectal liver (CLM) at Zealand University Hospital
  • Presence of at least one CLM evaluable and accessible by CEUS
  • (ECOG) performance status of 0-2.
  • Follow the conditions regarding fertility, pregnancy, or lactation:

    • Women of (WOCBP) are defined as women ranging from the period of menarche till the period, unless permanently sterile (e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy), Post-menopause is defined as no menses for 12 months without an alternative medical cause.
    • WOCBP should use a secure and highly effective (as stated in the "Recommendations related to contraception and pregnancy testing in clinical trials", version 1.1, section 4.1, from the Clinical Trials Facilitation and Coordination Group) during the entire period of the trial. In cases of uncertainty regarding pregnancy, pregnancy testing either as highly sensitive serum or urine pregnancy test will be used.

Exclusion criteria

Exclusion Criteria:

  • Oncologic systemic treatment 2 weeks prior to inclusion
  • Prior treatment with an (e.g. anti-PD-L1, anti PD-1, or anti-PD-L2)
  • Inability to reliably distinguish the study from other hepatic metastases using CEUS
  • Systemic treatment with either (>10 mg daily prednisolone equivalents) or other medications within 2 weeks prior inclusion. Inhaled or topical steroids and adrenal replacements doses > 10 mg daily prednisone equivalents are permitted in the absence of active disease.
  • Known history of (HIV), active or chronic , or C.
  • Pregnancy or lactation.
  • Confirmed dMMR positive primary tumors
  • Inability to comply with study protocol due to psychological, social, or logistical reasons.
  • for CEUS:

    • Known to SonoVue® or any other ultrasound contrast agent
    • Uncontrolled atrial hypertension
    • Known right-to-left intracardiac shunt
    • Severe pulmonary hypertension (SAP >90 mmHg)
    • Adult respiratory distress syndrome.
    • Known hypersensitivity to macrogols
    • Unstable ischemic heart disease or acute coronary syndrome
    • Severe lung disease, e.g. severe chronic obstructive lung disease
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • No intervention
    Historical control group

    The historical control group consists of 24 matched patients who underwent liver resection for one or more colorectal liver metastases at Rigshospitalet between 2022 and the end of 2024. These patients serve as a non-intervention comparison cohort.

  • Experimental
    Low-intensity CEUS intervention group

    12 eligible patients will be randomized to receive LI-CEUS intervention

    Other: Low-intensity contrast enhanced ultrasound

  • Experimental
    High-intensity CEUS intervention group

    12 eligible patients will be randomized to receive HI-CEUS intervention

    Other: High-intensity contrast enhanced ultrasound

Interventions

  • OtherLow-intensity contrast enhanced ultrasound

    The LI-CEUS arm will receive a 30-minute contrast-enhanced ultrasound session targeting a designated study metastasis. During the procedure, 1 mL of the ultrasound contrast agent SonoVue will be administered every 3 minutes throughout the entire session. Minimum 7 days after the intervention a biopsy of the study metastasis will be conducted.

  • OtherHigh-intensity contrast enhanced ultrasound

    The HI-CEUS intervention group will recieve a 30-minute CEUS procedure targeting a designated study metastasis. During the procedure, 1 mL of the ultrasound contrast agent SonoVue will be administered every 3 minutes throughout the entire session. A high-intensity ultrasound "flash" will be applied every 30 seconds. This "flash" consists of a brief sequence of ultrasound waves with a high mechanical index that causes complete destruction of microbubbles within the imaging field. Minimum 7 days after the intervention a biopsy of the study metastasis will be conducted.

06

What researchers measure

Primary outcomes

  1. Immune cell density (CD8+, CD3+) in colorectal liver metastases exposed to LI-CEUS or HI-CEUS, compared to controls.

    Time frame: ≥7 days after postinterventional

Secondary outcomes

  1. Number of participants in the intervention group with treatment-related adverse events assessed by CTCAE v5.0

    Time frame: Daily, until 7 days post-interventional

  2. Procedure success of LI-CEUS and HI-CEUS procedures as assessed by operator-defined completion of the planned intervention

    Time frame: Periinterventional

  3. Differential expression of immune-related genes between CEUS-exposed and control liver metastases

    Tissue bulk transcriptional analyses will be evaluated by the Nanostring nCounter platform. Immune-related spatial protein profiling of tumor regions will be evaluated by the GeoMx digital spatial profiler

    Time frame: ≥7 days postinterventional

  4. Systemic immune response assessed by changes in the circulating cytokine profiles following LI-CEUS and HI-CEUS

    Time frame: Pre- and ≥7 days postinterventional

  5. Frequency and type of technical issues encountered during LI-CEUS and HI-CEUS procedures assessed by the operator

    Time frame: Periinterventional

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — It is not yet decided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 10 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 26, 2026
StartActual
Feb 25, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 15, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365527
Responsible party
Ismail Gögenur (Professor, Zealand University Hospital) — Principal investigator
First posted
Jan 26, 2026
Start date
Feb 25, 2026
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Maja M Jeppesen, M.D
Contact
mjepp@regionsjaelland.dk
+45 47323011
Christian P Nolsøe, Professor
principal investigator · Center of Surgical Ultrasound, Surgical department of Zealand University Hospital
Ismail Gögenur, Professor
study director · Center of Surgical Science, Surgical department of Zealand University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion